Amgen, Novartis Expand Alzheimer's Collaboration with New Trial

Amgen and Novartis said today they will expand their two-year-old collaboration with the Banner Alzheimer’s Institute by launching a new Phase II/III trial designed to assess whether the oral beta-site APP-cleaving enzyme-1 (BACE1) inhibitor CNP520 codeveloped by the companies can prevent or delay symptoms in people at high risk for the memory-robbing ailment.The value of the expanded collaboration was not disclosed.The new trial—the Alzheimer's Prevention Initiative (API) Generation